Detecting aβ*56 oligomers in brain tissues.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 20967582)

Published in Methods Mol Biol on January 01, 2011

Authors

Mathew A Sherman1, Sylvain E Lesné

Author Affiliations

1: Department of Neuroscience, Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA.

Articles citing this

Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64

The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci (2012) 1.34

Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β. Brain (2015) 1.04

Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci (2014) 1.00

Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment. Transl Psychiatry (2013) 0.82

Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease. Sci Signal (2016) 0.81

Characterization of a Novel Mouse Model of Alzheimer's Disease--Amyloid Pathology and Unique β-Amyloid Oligomer Profile. PLoS One (2015) 0.80

Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport. J Neurosci (2016) 0.76

NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. Redox Biol (2017) 0.75

The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor. Brain (2017) 0.75

Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. MethodsX (2015) 0.75

Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits. Proc Natl Acad Sci U S A (2017) 0.75